The physiology of cardiovascular disease and innovative liposomal platforms for therapy Review uri icon


MeSH Major

  • Cardiovascular Diseases
  • Drug Carriers
  • Liposomes
  • Nanomedicine
  • Nanoparticles


  • Heart disease remains the major cause of death in males and females, emphasizing the need for novel strategies to improve patient treatment and survival. A therapeutic approach, still in its infancy, is the development of site-specific drug-delivery systems. Nanoparticle-based delivery systems, such as liposomes, have evolved into robust platforms for site-specific delivery of therapeutics. In this review, the clinical impact of cardiovascular disease and the pathophysiology of different subsets of the disease are described. Potential pathological targets for therapy are introduced, and promising advances in nanotherapeutic cardiovascular applications involving liposomal platforms are presented.

publication date

  • February 7, 2013



  • Review



  • eng

PubMed Central ID

  • PMC3572823

Digital Object Identifier (DOI)

  • 10.2147/IJN.S30599

PubMed ID

  • 23413209

Additional Document Info

start page

  • 629

end page

  • 40


  • 8